Cargando…
FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. The multityrosine kinase inhibitor sorafenib is used in the therapy of advanced disease. However, the effects of sorafenib are limited, and combination treatments aiming at improved survival are encouraged...
Autores principales: | Ahmed, Dilruba, de Verdier, Petra J, Ryk, Charlotta, Lunqe, Oscar, Stål, Per, Flygare, Jenny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618642/ https://www.ncbi.nlm.nih.gov/pubmed/26516583 http://dx.doi.org/10.1002/prp2.171 |
Ejemplares similares
-
The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
por: Patmanathan, Sathya Narayanan, et al.
Publicado: (2015) -
The emerging role of FTY720 (Fingolimod) in cancer treatment
por: White, Christopher, et al.
Publicado: (2016) -
Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011) -
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011) -
The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage
por: Stradner, Martin H, et al.
Publicado: (2011)